Yamada K, Nabeshima T
Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Showa-ku, 466-8560, Nagoya, Japan.
Pharmacol Ther. 2000 Nov;88(2):93-113. doi: 10.1016/s0163-7258(00)00081-4.
Alzheimer's disease (AD) is the most common cause of progressive decline of cognitive function in aged humans, and is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. Some, but not all, of the neuropathological alterations and cognitive impairment in AD can be reproduced genetically and pharmacologically in animals. It should be possible to discover novel drugs that slow the progress or alleviate the clinical symptoms of AD by using these animal models. We review the recent progress in the development of animal models of AD and discuss how to use these model animals to evaluate novel anti-dementia drugs.
阿尔茨海默病(AD)是老年人认知功能进行性衰退的最常见原因,其特征是存在大量老年斑和神经原纤维缠结,并伴有神经元丢失。AD中的一些(但并非全部)神经病理学改变和认知障碍可以在动物中通过遗传和药理学方法再现。利用这些动物模型应该有可能发现减缓AD进展或减轻其临床症状的新型药物。我们综述了AD动物模型开发的最新进展,并讨论如何使用这些模型动物来评估新型抗痴呆药物。